Vital Signs: 05 February 2010 – BTA
February 5, 2010
Biota Holdings Limited (BTA) said it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the December 2009 quarter. The company said it would report first half indicative Relenza royalty income of $56.7 million, up from $3.8 million in 2008, when it releases its Interim Report on 17 February 2010.
Leave a Reply